Repligen 获得了华尔街禅宗的“持有”评级，而 Regulus Therapeutics 尽管最近有所下降，但评级上调。 Repligen gets a "hold" rating from Wall Street Zen, while Regulus Therapeutics sees a rating upgrade despite recent losses.

华尔街禅将Repligen的评级降至"持有"级,尽管该公司的收益超出预期,报道每股收益0.39美元,收入增长10.4%. Wall Street Zen downgraded Repligen to a "hold" rating despite the company beating earnings expectations, reporting $0.39 EPS and a 10.4% revenue increase. D Boral Capital重申了对Reviva制药公司的“买”评级,该评级也比收入估计数高。 D. Boral Capital reaffirmed a "buy" rating for Reviva Pharmaceuticals, which also beat earnings estimates. Regulus The Medicaltics看到华尔街Zen的评分升级为“Hold”, 公司股票在最后一个季度增加了13.7%, Regulus Therapeutics saw a rating upgrade to "Hold" from Wall Street Zen, with the company's stock increasing by 13.7% in the last quarter despite a loss per share.